Immunotherapy for combined pulmonary fibrosis and emphysema with advanced lung cancer: two case reports and a concise review

作者全名："Tan, Xianglan; Tang, Xi; Jiang, Yu"

作者地址："[Tan, Xianglan; Tang, Xi; Jiang, Yu] Chongqing Med Univ, Univ Town Hosp, Dept Resp & Crit Care Med, Chongqing, Peoples R China; [Jiang, Yu] Chongqing Med Univ, Univ Town Hosp, Dept Resp & Crit Care Med, Chongqing 401331, Peoples R China"

通信作者："Jiang, Y (通讯作者)，Chongqing Med Univ, Univ Town Hosp, Dept Resp & Crit Care Med, Chongqing 401331, Peoples R China."

来源：TRANSLATIONAL CANCER RESEARCH

ESI学科分类：BIOLOGY & BIOCHEMISTRY

WOS号：WOS:000874378500001

JCR分区：Q4

影响因子：0.9

年份：2022

卷号：　

期号：　

开始页：　

结束页：　

文献类型：Review; Early Access

关键词：Advanced lung cancer; combined pulmonary fibrosis and emphysema (CPFE); immunotherapy; case report

摘要："Background: It is unclear whether immunotherapy for combined pulmonary fibrosis and emphysema (CPFE) with advanced lung cancer (CPFE-LC) is safe.Case Description: We reported on two cases of primary CPFE-LC, where the initial focus was on the lung cancer and not on the CPFE. The two patients underwent surgical resections of the lung cancer, and were placed on a combination of immunotherapy and chemotherapy after progressive lung cancer was observed. One patient showed a worsening of respiratory symptoms with increased consolidation and ground-glass shadows, and an increased extent of honeycombing and other fibrosis on high-resolution computed tomography (HRCT) (>10%). He suffered acute exacerbations of interstitial lung disease (AE-ILD) after successful treatment with radiotherapy and follow-up immunotherapy and developed a progressivefibrosing phenotype. The other patient had a tumor that had shrunk with no progression of the CPFE fibrosis. The two patients died of AE-ILD and tumor invasion, respectively.Conclusions: Immunotherapy combined with comprehensive therapy may provide benefits for patients with CPFE-LC to a certain extent. However, immune-related adverse effects may limit the use of immunotherapy in CPFE-LC, and the choice of immunotherapy should be cautious in CPFE-LC with a history of radiation pneumonitis or AE-ILD."

基金机构：general project of Chongqing Natural Science Foundation; [cstc2020jcyj-msxmX0359]

基金资助正文：Acknowledgments Funding: This work was supported by general project of Chongqing Natural Science Foundation (No. cstc2020jcyj-msxmX0359) .